Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy

Stefano Caselli1, Martin S Maron2, Josè A Urbano-Moral2

  • 1Institute of Sports Medicine and Science, Rome, Italy.

Insights

Differentiating hypertrophic cardiomyopathy (HC) from athlete's heart in athletes with borderline left ventricular (LV) wall thickness is crucial. Left ventricular cavity size, specifically <54 mm, is the most reliable echocardiographic marker for distinguishing HC from athlete's heart.

Area of Science:

  • Cardiology
  • Sports Medicine
  • Diagnostic Imaging

Background:

  • Distinguishing hypertrophic cardiomyopathy (HC) from athlete's heart is challenging in young athletes with borderline left ventricular (LV) wall thickness (13-15 mm).
  • Accurate differentiation is vital for appropriate clinical management and to prevent misdiagnosis.

Purpose of the Study:

  • To evaluate the diagnostic utility of simple echocardiographic and clinical variables for differentiating HC from athlete's heart.
  • To identify reliable criteria for distinguishing these conditions in the "gray zone" of LV hypertrophy.

Main Methods:

  • A comparative study involving 28 athletes without cardiovascular disease and 25 untrained patients with HC, matched for LV wall thickness, age, and gender.
  • Analysis of clinical, electrocardiographic, and echocardiographic parameters including LV cavity dimensions, aortic root, left atrium size, and e' velocity via tissue Doppler imaging.

Main Results:

  • Athletes exhibited larger LV cavities (60±3 vs 45±5 mm), aortic roots (34±3 vs 30±3 mm), and left atria (42±4 vs 33±5 mm) compared to HC patients.
  • An LV cavity size <54 mm demonstrated 100% sensitivity and specificity for differentiating HC from athlete's heart.
  • Higher e' velocity in athletes (12.5±1.9 vs 9.3±2.3 cm/s) and absence of diffuse T-wave inversion on ECG were also significant differentiating factors.

Conclusions:

  • Left ventricular cavity size (<54 mm) is the most reliable echocardiographic criterion for differentiating hypertrophic cardiomyopathy from athlete's heart in cases of borderline LV hypertrophy.
  • Additional factors like left atrial size, diastolic function (e' velocity), electrocardiographic findings (T-wave inversion), and family history aid in the differential diagnosis.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
793
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
743
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
809
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
775
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
1.1K